Diazepam-Binding Inhibitor: A Brain Neuropeptide Present in Human Spinal Fluid: Studies in Depression, Schizophrenia, and Alzheimer's Disease

Maria L. Barbaccia, Erminio Costa, Patrizia Ferrero, Alessandro Guidotti, Alec Roy, Trey Sunderland, David Pickar, Steven M. Paul, Frederick K. Goodwin

Research output: Contribution to journalArticle

Abstract

Diazepam-binding inhibitor is a novel peptide purified to homogeneity from rat and human brain. Diazepam-binding inhibitor is present, though not exclusively, in γ-aminobutyric acid (GABA)—containing neurons where it is believed to inhibit GABAergic neurotransmission mediated by GABA by binding to the benzodiazepine-GABA receptor complex. Since an impairment of central GABAergic tone has been postulated to be associated with a number of neuropsychiatric disorders, we measured human diazepam-binding inhibitor immunoreactivity in the cerebrospinal fluid (CSF) of patients suffering from endogenous depression, schizophrenia, and dementia of the Alzheimer's type. Patients with major depression had significantly higher concentrations of human diazepam-binding inhibitor immunoreactivity in CSF when compared with age- and sex-matched normal volunteers, while no difference in CSF diazepam-binding inhibitor immunoreactivity was found in schizophrenics or patients with dementia of the Alzheimer's type when compared with controls. The possibility is discussed that the increased CSF human diazepam-binding inhibitor immunoreactivity observed in depressed patients may represent a functional disinhibition of GABAergic neurotransmission associated with depression.

Original languageEnglish (US)
Pages (from-to)1143-1147
Number of pages5
JournalArchives of General Psychiatry
Volume43
Issue number12
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Diazepam Binding Inhibitor
Neuropeptides
Schizophrenia
Alzheimer Disease
Depression
Cerebrospinal Fluid
Brain
Synaptic Transmission
Aminobutyrates
GABAergic Neurons
GABA-A Receptors
Depressive Disorder
gamma-Aminobutyric Acid
Alzheimer's Disease
Healthy Volunteers
Peptides

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Diazepam-Binding Inhibitor : A Brain Neuropeptide Present in Human Spinal Fluid: Studies in Depression, Schizophrenia, and Alzheimer's Disease. / Barbaccia, Maria L.; Costa, Erminio; Ferrero, Patrizia; Guidotti, Alessandro; Roy, Alec; Sunderland, Trey; Pickar, David; Paul, Steven M.; Goodwin, Frederick K.

In: Archives of General Psychiatry, Vol. 43, No. 12, 1986, p. 1143-1147.

Research output: Contribution to journalArticle

Barbaccia, ML, Costa, E, Ferrero, P, Guidotti, A, Roy, A, Sunderland, T, Pickar, D, Paul, SM & Goodwin, FK 1986, 'Diazepam-Binding Inhibitor: A Brain Neuropeptide Present in Human Spinal Fluid: Studies in Depression, Schizophrenia, and Alzheimer's Disease', Archives of General Psychiatry, vol. 43, no. 12, pp. 1143-1147. https://doi.org/10.1001/archpsyc.1986.01800120029007
Barbaccia, Maria L. ; Costa, Erminio ; Ferrero, Patrizia ; Guidotti, Alessandro ; Roy, Alec ; Sunderland, Trey ; Pickar, David ; Paul, Steven M. ; Goodwin, Frederick K. / Diazepam-Binding Inhibitor : A Brain Neuropeptide Present in Human Spinal Fluid: Studies in Depression, Schizophrenia, and Alzheimer's Disease. In: Archives of General Psychiatry. 1986 ; Vol. 43, No. 12. pp. 1143-1147.
@article{ad9e2375228c41668d42736538d41cd8,
title = "Diazepam-Binding Inhibitor: A Brain Neuropeptide Present in Human Spinal Fluid: Studies in Depression, Schizophrenia, and Alzheimer's Disease",
abstract = "Diazepam-binding inhibitor is a novel peptide purified to homogeneity from rat and human brain. Diazepam-binding inhibitor is present, though not exclusively, in γ-aminobutyric acid (GABA)—containing neurons where it is believed to inhibit GABAergic neurotransmission mediated by GABA by binding to the benzodiazepine-GABA receptor complex. Since an impairment of central GABAergic tone has been postulated to be associated with a number of neuropsychiatric disorders, we measured human diazepam-binding inhibitor immunoreactivity in the cerebrospinal fluid (CSF) of patients suffering from endogenous depression, schizophrenia, and dementia of the Alzheimer's type. Patients with major depression had significantly higher concentrations of human diazepam-binding inhibitor immunoreactivity in CSF when compared with age- and sex-matched normal volunteers, while no difference in CSF diazepam-binding inhibitor immunoreactivity was found in schizophrenics or patients with dementia of the Alzheimer's type when compared with controls. The possibility is discussed that the increased CSF human diazepam-binding inhibitor immunoreactivity observed in depressed patients may represent a functional disinhibition of GABAergic neurotransmission associated with depression.",
author = "Barbaccia, {Maria L.} and Erminio Costa and Patrizia Ferrero and Alessandro Guidotti and Alec Roy and Trey Sunderland and David Pickar and Paul, {Steven M.} and Goodwin, {Frederick K.}",
year = "1986",
doi = "10.1001/archpsyc.1986.01800120029007",
language = "English (US)",
volume = "43",
pages = "1143--1147",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Diazepam-Binding Inhibitor

T2 - A Brain Neuropeptide Present in Human Spinal Fluid: Studies in Depression, Schizophrenia, and Alzheimer's Disease

AU - Barbaccia, Maria L.

AU - Costa, Erminio

AU - Ferrero, Patrizia

AU - Guidotti, Alessandro

AU - Roy, Alec

AU - Sunderland, Trey

AU - Pickar, David

AU - Paul, Steven M.

AU - Goodwin, Frederick K.

PY - 1986

Y1 - 1986

N2 - Diazepam-binding inhibitor is a novel peptide purified to homogeneity from rat and human brain. Diazepam-binding inhibitor is present, though not exclusively, in γ-aminobutyric acid (GABA)—containing neurons where it is believed to inhibit GABAergic neurotransmission mediated by GABA by binding to the benzodiazepine-GABA receptor complex. Since an impairment of central GABAergic tone has been postulated to be associated with a number of neuropsychiatric disorders, we measured human diazepam-binding inhibitor immunoreactivity in the cerebrospinal fluid (CSF) of patients suffering from endogenous depression, schizophrenia, and dementia of the Alzheimer's type. Patients with major depression had significantly higher concentrations of human diazepam-binding inhibitor immunoreactivity in CSF when compared with age- and sex-matched normal volunteers, while no difference in CSF diazepam-binding inhibitor immunoreactivity was found in schizophrenics or patients with dementia of the Alzheimer's type when compared with controls. The possibility is discussed that the increased CSF human diazepam-binding inhibitor immunoreactivity observed in depressed patients may represent a functional disinhibition of GABAergic neurotransmission associated with depression.

AB - Diazepam-binding inhibitor is a novel peptide purified to homogeneity from rat and human brain. Diazepam-binding inhibitor is present, though not exclusively, in γ-aminobutyric acid (GABA)—containing neurons where it is believed to inhibit GABAergic neurotransmission mediated by GABA by binding to the benzodiazepine-GABA receptor complex. Since an impairment of central GABAergic tone has been postulated to be associated with a number of neuropsychiatric disorders, we measured human diazepam-binding inhibitor immunoreactivity in the cerebrospinal fluid (CSF) of patients suffering from endogenous depression, schizophrenia, and dementia of the Alzheimer's type. Patients with major depression had significantly higher concentrations of human diazepam-binding inhibitor immunoreactivity in CSF when compared with age- and sex-matched normal volunteers, while no difference in CSF diazepam-binding inhibitor immunoreactivity was found in schizophrenics or patients with dementia of the Alzheimer's type when compared with controls. The possibility is discussed that the increased CSF human diazepam-binding inhibitor immunoreactivity observed in depressed patients may represent a functional disinhibition of GABAergic neurotransmission associated with depression.

UR - http://www.scopus.com/inward/record.url?scp=0022998560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022998560&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1986.01800120029007

DO - 10.1001/archpsyc.1986.01800120029007

M3 - Article

C2 - 3022663

AN - SCOPUS:0022998560

VL - 43

SP - 1143

EP - 1147

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 12

ER -